Method for inhibiting bone resorption
AssigneeMerck & Co., Inc.
InventorsAnastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Claims65
A method for inhibiting bone resorption in a mammal, in need thereof, comprising sequentially orally administering to said mammal, in need thereof a pharmaceutically effective amount of a unit dosage of a histamine H2 receptor blocker or a proton pump inhibitor and a unit dosage of a bisphosphonate according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.
A method for treating osteoporosis in a mammal in need thereof comprising sequentially orally administering to said mammal a pharmaceutically effective amount of a unit dosage of a histamine H2 receptor blocker or a proton pump inhibitor and a unit dosage of a bisphosphonate according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.
A method for preventing osteoporosis in a mammal, in need thereof, comprising sequentially orally administering to said mammal, in need thereof a pharmaceutically effective amount of a unit dosage of a histamine H2 receptor blocker or a proton pump inhibitor and a unit dosage of a bisphosphonate according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.
A kit comprising, comprising:
- (a) at least one pharmaceutically effective unit dosage of a bisphosphonate for oral administration, and
- (b) at least one pharmaceutically effective unit dosage of a histamine H2 receptor blocker or a proton pump inhibitor.
Dependencies are inferred from the claim text.